Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
about
Use of the tumor necrosis factor-blockers for Crohn's diseaseEtanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.Tocilizumab: is there life beyond anti-TNF blockade?Assessing response and loss of response to biological therapies in IBD.Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity.Prevention of acute adverse events related to infliximab infusions in pediatric patients.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Familial Association of Granulocyte-Macrophage Colony Stimulating Factor Autoantibodies in Inflammatory Bowel Disease.Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease.Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease.Granulocyte Macrophage Colony-Stimulating Factor Auto-Antibodies and Disease Relapse in Inflammatory Bowel Disease
P2860
Q27030762-C2C004F5-7520-4521-8C66-D0168B074FACQ35060214-A685C9D5-8D38-439F-B102-6060434D52D0Q37832771-97B83BF2-3FDB-4481-8C60-C9A60B857C75Q37856191-F4806146-8241-499E-BA7B-B625B88CAC78Q38063585-AF166F05-7A03-44B4-B476-23F80824C522Q42437439-3D0D4B36-2FC4-4177-9EEC-44A3DDF2177FQ43035857-0073A8B1-BE43-4511-A191-39021452365AQ43988900-C9A89904-32ED-44AD-BDBB-96FDB0C60E04Q47350920-3447236A-9B98-4B8F-8CA7-762B7C5A9C2DQ50713607-A496E62E-3F06-45A2-8420-F8EEDEDF36BCQ52967310-60C49C06-3838-4B0A-A344-B4440E2D3A42Q53331247-F54F48F0-7080-40FB-9515-3F0A7AEFAF1DQ57913848-CB3B73C6-D681-45D5-B51D-276A53BF555C
P2860
Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Non-response to infliximab may ...... rosis factor-alpha antibodies.
@en
Non-response to infliximab may ...... rosis factor-alpha antibodies.
@nl
type
label
Non-response to infliximab may ...... rosis factor-alpha antibodies.
@en
Non-response to infliximab may ...... rosis factor-alpha antibodies.
@nl
prefLabel
Non-response to infliximab may ...... rosis factor-alpha antibodies.
@en
Non-response to infliximab may ...... rosis factor-alpha antibodies.
@nl
P2093
P2860
P1476
Non-response to infliximab may ...... rosis factor-alpha antibodies.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2249.2008.03773.X
P577
2008-09-23T00:00:00Z